Why BGPT?
logo

Author review tools

For authors: check each claim against the cited experiments and reported results before submission, with provenance and limits.Know what the science actually supports before you trust the answer.

Press Enter ↵ to check



    Explore by Goal









     Quick Explanation


    D.R. Cornblath — scientific impact & rigor snapshot
    • Clinical neuroimmunology/neurophysiology footprint: frequently cited work spanning Guillain-Barré syndrome (GBS) diagnostics/classification and related neuromuscular syndromes (e.g., diagnostic criteria updates and electrophysiologic classification) (10.1002/ana.410270707) (10.1002/ana.410440512) (10.1016/S0140-6736(05)67665-9).
    • Methodological emphasis: strong signal toward electrophysiology-based clinical phenotyping and diagnostic frameworks (with downstream relevance for trials/management) (10.1002/ana.410440512) (10.1097/ccm.0b013e3181b6ef67).
    • Key caveat: without reviewing full text (and without outcome stratification details), citation counts alone can’t establish causal scientific advancement; they can reflect field centrality and consensus building.



     Long Explanation


    Author Review: D.R. Cornblath
    Scope of this review: scientific contribution assessment based on the provided paper metadata (titles, years, citation counts, DOIs) and OpenAlex-style publication/year distributions. Because full-text methods/results were not provided for all items, I evaluate strength using only the evidence explicitly present in the supplied extract.
    1) Visual evidence: publication output over time
    Data source: provided counts_by_year for one matched OpenAlex author entry (“top_author”).
    2) Visual evidence: citation density of top works
    Data source: provided top_works list (title/year/type/doi/cited_by_count).
    3) Evidence-based assessment of scientific contribution (only what the extract supports)
    3.1 Strongest supported themes from the provided works
    • Diagnostic criteria / classification frameworks for GBS. Example: reaffirmed diagnostic criteria with expanded electrodiagnostic detail (10.1002/ana.410270707) and a large electrophysiologic/serologic dataset enabling clinical associations and outcome stratification (10.1002/ana.410440512) (as described in the extract).
    • Clinical neuromuscular phenotyping using electrophysiology and syndrome-level characterization. The electrophysiologic classification work explicitly reports testing within 15 days of symptom onset in a 369-patient cohort enrolled in a trial comparing plasma exchange/IVIg/both (10.1002/ana.410440512).
    • Guideline/consensus work in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The provided guideline revision includes diagnostic criteria and treatment recommendations (at least IVIg mentioned in the extract) (10.1111/j.1468-1331.2009.02930.x).
    • Mechanism-informed clinical neurology and genetics (ALS4 via helicase mutations). The extract lists “DNA/RNA Helicase Gene Mutations in … ALS4” in AJHG (10.1086/421054).
    3.2 Strengths (what the citations imply, with skepticism)
    • Centrality of diagnostic work: High cited-by counts for diagnostic criteria and electrophysiologic classification suggest the community repeatedly relies on these frameworks for trial enrollment, stratification, and clinical interpretation. Example works include diagnostic criteria reaffirmation and classification with clinical associations/outcome in a 369-patient cohort .
    • Translational coverage: The presence of guideline-level work (CIDP) suggests competence in synthesizing evidence into usable diagnostic/treatment frameworks.
    • Method diversity: While the dominant signal is clinical neuromuscular syndromes, the extract also includes a genetics paper (ALS4 helicase mutations) .
    3.3 Limitations & red flags to check (scientific, not social)
    • Citation counts are not experimental proof. High citation may reflect consensus adoption, educational centrality, or being frequently referenced in guidelines—not necessarily that every claim in those works remains best-in-class as methods improve.
    • Evidence strength depends on full-text details. For example, guideline and diagnostic-criteria papers may include expert consensus components; without the complete methodology and update rationale, it’s hard to gauge how robust each recommendation remains today.
    • Generalizability across populations can vary. Some extract-listed studies are region-specific (e.g., “northern China” GBS phenotype comparisons). Without full sampling details and replication context, extrapolation should be cautious. Example listed work .
    • Risk of “framework ossification.” Diagnostic criteria can become widely used even after later revisions; the best scientific check is tracking subsequent updates and validation studies against newer electrophysiologic/clinical technologies.
    4) What would most disprove/alter this assessment?
    • Demonstration that widely used diagnostic/classification criteria fail to predict outcomes reliably when validated in independent cohorts using modern protocols (electrodiagnostic standards, timing windows, and inter-rater reliability).
    • Clear retractions/corrections of key diagnostic claims (none are provided in the extract).
    • Evidence that mechanistic claims (e.g., region-specific infectious associations) are substantially confounded by sampling bias, incomplete microbiologic characterization, or antibody testing artifacts—requires full-text methods.
    5) Citation anchor list (from provided top works)
    Work Year Type DOI Cited-by (provided)
    Assessment of current diagnostic criteria for Guillain-Barré syndrome1990review10.1002/ana.4102707071901
    Guillain-Barré syndrome2005review10.1016/S0140-6736(05)67665-91677
    CIDP guideline revision (EFNS/PNS)2010article10.1111/j.1468-1331.2009.02930.x1126
    Electrophysiological classification of GBS: Clinical associations and outcome1998article10.1002/ana.410440512932
    DNA/RNA Helicase Gene Mutations in ALS42004article10.1086/421054810
    GBS in northern China vs Campylobacter/anti-glycolipid antibodies1995article10.1093/brain/118.3.597758
    Spectrum of neuropathy in diabetes and impaired glucose tolerance2003article10.1212/WNL.60.1.108702
    A framework for diagnosing and classifying ICU-acquired weakness2009review10.1097/CCM.0b013e3181b6ef67663
    Acute motor axonal neuropathy: A frequent cause of acute flaccid paralysis in China1993article10.1002/ana.410330402623
    Rhabdomyolysis2005article10.1097/01.md.0000188565.48918.41615
    Run science agent (full-text + evidence extraction)
    This can fetch additional evidence and critically summarize methods/results from the cited works (where available), then re-score rigor/strength using concrete experimental details.


    Feedback:    

    Updated: April 01, 2026

     BGPT Author Review


    Scientific Quality

    80%

    From the provided publication evidence, Cornblath appears scientifically strong in clinical neurodiagnostics: multiple high-citation works on Guillain-Barré syndrome diagnostic criteria and electrophysiologic classification, plus guideline-level synthesis for CIDP. However, this score is limited by the lack of full-text methods/results in the prompt; citation centrality may not fully capture rigor, and diagnostic frameworks require ongoing validation. Overall: high domain influence, likely strong methodology, but incomplete verifiability from supplied data.


    Communication Quality

    80%

    Titles and metadata suggest clear clinical framing (diagnostic criteria, classification, frameworks, guidelines). High-citation review/guideline work typically requires effective synthesis. Still, no direct abstract/full-text excerpt quality assessment is provided, so the score is based on inferred structure rather than measured writing clarity.


    Author Novelty

    60%

    The cited contributions look more like methodological consolidation and diagnostic framework development than clearly disruptive mechanistic novelty (based on the provided titles/types). Without full-text, novelty cannot be confirmed; it may include novel electrophysiologic classification strategies that later became standards.


    Scientific Rigor

    70%

    The provided metadata includes a substantial cohort with defined testing windows and trial enrollment for GBS classification . That supports moderate-to-high rigor. But diagnostic criteria/guidelines often incorporate consensus and require independent validation; without that information, rigor is scored conservatively.

     Hypothesis Graveyard


    A single infectious trigger universally explains GBS phenotypes across regions; this is unlikely because region-specific studies explicitly report differing clinical/biologic patterns .


    Diagnostic criteria are fully transportable across settings without recalibration; this is implausible given known effects of timing, measurement protocols, and population differences, and because the extract includes both region-specific and framework-level papers .

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending